MindMed Inc. MNMD reported favorable results for one of its proprietary compounds.
The Phase 1 trial of MM-110 included 108 healthy volunteers and was designed to study the pharmacokinetics and neurocognitive effects of the substance, ensuring its safety and tolerability. MM-110 is designed to treat opioid withdrawal.
A total of 72 participants received up to 325 mg of the ibogaine analog twice on a single day or a placebo. 51 were administered the compound, while 21 received the placebo.
Likewise, 36 participants were administered either up to 90mg of MM-110 twice daily for seven days, or a placebo. In this case, 26 people received the substance and 10 were given the placebo.
Among the observations and results, it was found that MM-110 was well-tolerated with no serious adverse effects. In addition, the pharmacokinetic profile was consistent and clinical laboratory parameters didn’t show findings of concern. The company is looking forward to carrying out a Phase 2 study in the second quarter of 2022.
Last month, MindMed reported promising data on a study to treat generalized anxiety disorder with LSD. Last year, the company announced a study evaluating the effects of combining MDMA and LSD for therapeutic purposes.
Daniel R Karlin, chief medical officer of MindMed, said: "As there is a major unmet need to address the ongoing and ever-growing opioid crisis, we are very pleased with the results from our Phase 1 trial, which underscore the potential clinical utility of MM-110 to safely mitigate symptoms of opioid withdrawal.”
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!